Where does Alpine Immune Sciences, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Alpine Immune Sciences, Inc. ranks #12,343 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Alpine Immune Sciences, Inc. hold?

Alpine Immune Sciences, Inc. holds 24 US utility patents granted between 2021 and 2025, spanning 7 technology areas.

What is Alpine Immune Sciences, Inc.'s Innovation Score?

Alpine Immune Sciences, Inc. has an Innovation Score of 50.5 out of 100 (top 13% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Alpine Immune Sciences, Inc. focus on?

Alpine Immune Sciences, Inc.'s top technology area is C07K (Peptides) with 24 patents, ranking #400 of 3,615 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Alpine Immune Sciences, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Alpine Immune Sciences, Inc..

What does claim depth mean for Alpine Immune Sciences, Inc.'s patents?

Alpine Immune Sciences, Inc.'s patents average 24.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Alpine Immune Sciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Alpine Immune Sciences, Inc.

USPTO PatentsView assignee record - 24 granted patents across 7 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Alpine ranks #12,343 of 49,997 tracked US assignees by granted-patent volume, with 24 patents across 7 technology areas.

#12,343
of 49,997 US assignees by volume: Top 13%
by Innovation Score (50.5/100): 24.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R12343 · US Corporation #12,343 · 24 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 24 grants
UPPER-Q #12,343/49,997
PHOTO-FINISH Adamis Pharmaceuticals
CPC-NARROW C07K · 7 areas
INNOV-PAR 50.5/100
CLAIMS-DENSE 24.1 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Adamis Pharmaceuticals Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Alpine’s 50.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.1 pts (22%) Velocity 15.6 pts (31%) Breadth 9.4 pts (19%) Claim depth 14.4 pts (29%)

Qualcomm Incorporated · highest

85
Alpine Immune Sciences · this assignee

50
3D Lighting… · lowest

7

What this shows Alpine's Innovation Score is 50.5/100 (top 13% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Alpine?

Each dot is one of Alpine’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Alpine’s own 24.1 claims/patent is ABOVE the 13.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Alpine vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Alpine's grants concentrate

Alpine Immune Sciences, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2022 (7 grants) versus a trough of 2 in 2024. By volume, Alpine sits between Adamis Pharmaceuticals Corporation and Apellis Pharmaceuticals, Inc..

Alpine's three-year grant acceleration

Alpine Immune Sciences, Inc. shows 14 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Adamis Pharmaceut…

24
Advance Research…

24
Airlite Plastics

24
Alakai

24
Ameriglobe

24
Amprius

24
Anonyome Labs

24
Apellis Pharmaceu…

24
Alpine Immune Sci… ◀

24

What this shows Alpine holds 24 patents at rank #12,350, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Alpine

By rank, the assignees closest to #12,350 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Alpine's primary technology class.

Alpine's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

50 Top 13% higher than 87% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Alpine Immune Sciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	6	25.0%
2022	7	29.2%
2023	5	20.8%
2024	2	8.3%
2025partial year	4	16.7%

Which technologies does Alpine Immune Sciences, Inc. patent most?

C07K - Peptides 24

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 22

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 21

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 10

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 7

Y02A - Technologies FOR Adaptation TO Climate Change 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Alpine Immune Sciences, Inc.'s patent record in context - here's where to go next.

Alpine Immune Sciences, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #12,343 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Alpine Immune Sciences, Inc. against Adamis Pharmaceuticals Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 50.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.